Related Experiment Video
Updated: Dec 22, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Successful Liposteroid Therapy for a Recurrent Idiopathic Pulmonary Hemosiderosis with Down Syndrome
Hiromi Tobai1,2, Jun Yano1, Norio Sato1
1Department of Pediatrics, Iwate Prefectural Iwai Hospital, Ichinoseki, Japan.
Insights
Idiopathic pulmonary hemosiderosis (IPH) in a child with Down syndrome was successfully managed with liposteroid therapy. This treatment controlled recurrent bleeding and significantly improved the patient's quality of life.
Area of Science:
- Pediatric Hematology
- Pulmonology
- Rare Diseases
Background:
- Idiopathic pulmonary hemosiderosis (IPH) is a rare, life-threatening condition impacting lung health.
- Early diagnosis and management are crucial for improving prognosis and quality of life (QOL).
- IPH in Down syndrome patients is associated with a poorer prognosis.
Observation:
- A 2-year-old girl with Down syndrome was diagnosed with IPH after severe pulmonary hemorrhage.
- The patient experienced recurrent IPH episodes during corticosteroid tapering.
- Liposteroid therapy was initiated for management.
Findings:
- Successful control of recurrent idiopathic pulmonary hemosiderosis was achieved with liposteroid therapy.
- Liposteroid treatment allowed for a tapering dose of corticosteroids.
- Significant improvement in the patient's quality of life was observed.
Implications:
- Liposteroid therapy presents a promising treatment option for managing IPH, particularly in complex cases.
- This approach may offer an alternative for patients with Down syndrome experiencing IPH.
- Effective management of IPH can lead to substantial improvements in patient QOL.
Abstract:
Idiopathic pulmonary hemosiderosis (IPH) is a rare and life-threatening disorder. Early diagnosis and appropriate management are essential for their better prognosis and patients' quality of life (QOL). It is considered that Down syndrome patients with IPH have a worse prognosis compared to other IPH cases. A 2-year-old girl with Down syndrome received the diagnosis of IPH after two episodes of massive pulmonary hemorrhage requiring assist ventilation, who suffered from recurrent IPH during tapering period of oral corticosteroid, started liposteroid therapy. We report here a case of successful control of recurrent IPH and improved QOL enormously with tapering dose of corticosteroid after starting liposteroid therapy.
